We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

287 hedge funds and large institutions have $3.02B invested in Amedisys in 2023 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 111 increasing their positions, 82 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 82

18% more funds holding in top 10

Funds holding in top 10: 1113 (+2)

10% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 39

8% more capital invested

Capital invested by funds: $2.79B → $3.02B (+$225M)

6.7% more ownership

Funds ownership: 90.64%97.34% (+6.7%)

0% more funds holding

Funds holding: 286287 (+1)

79% less call options, than puts

Call options by funds: $18.2M | Put options by funds: $88.3M

Holders
287
Holders Change
+1
Holders Change %
+0.35%
% of All Funds
4.18%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.19%
New
43
Increased
111
Reduced
82
Closed
39
Calls
$18.2M
Puts
$88.3M
Net Calls
-$70.1M
Net Calls Change
+$5.46M
Name Holding Trade Value Shares
Change
Change in
Stake
AA
26
AQR Arbitrage
Connecticut
$33.4M +$3.52M +37,694 +12%
SCM
27
Segantii Capital Management
Hong Kong
$32.8M +$32.2M +344,795 New
Charles Schwab
28
Charles Schwab
California
$29.7M +$787K +8,422 +3%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$27.3M -$948K -10,152 -3%
VNIM
30
Vaughan Nelson Investment Management
Texas
$27.2M +$1.09M +11,670 +4%
Bank of Nova Scotia
31
Bank of Nova Scotia
Ontario, Canada
$26M -$1.13M -12,061 -4%
Northern Trust
32
Northern Trust
Illinois
$23.1M -$339K -3,632 -1%
Calamos Advisors
33
Calamos Advisors
Illinois
$23M +$22.6M +242,110 New
Amundi
34
Amundi
France
$21.9M -$4.98M -53,353 -19%
HCM
35
Highbridge Capital Management
New York
$21.4M +$14.5M +155,056 +222%
GF
36
Gabelli Funds
New York
$21.3M +$4.14M +44,340 +25%
Renaissance Technologies
37
Renaissance Technologies
New York
$20.3M +$20M +213,655 New
Boston Partners
38
Boston Partners
Massachusetts
$19.4M -$748K -8,004 -4%
GCIA
39
Gabelli & Co Investment Advisers
New York
$19.2M +$3.6M +38,550 +24%
RIM
40
Ranger Investment Management
Texas
$18.9M +$108K +1,155 +0.6%
Citigroup
41
Citigroup
New York
$18.2M +$939K +10,053 +6%
IG
42
ING Group
Netherlands
$18M
Qube Research & Technologies (QRT)
43
Qube Research & Technologies (QRT)
United Kingdom
$17.7M +$15.4M +165,371 +779%
JP Morgan Chase
44
JP Morgan Chase
New York
$17.2M +$9.06M +97,017 +116%
MP
45
Mangrove Partners
Connecticut
$16.1M +$15.8M +169,634 New
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$15.1M -$238K -2,543 -2%
LI
47
Leeward Investments
Massachusetts
$15.1M -$127K -1,359 -0.8%
National Bank of Canada
48
National Bank of Canada
Quebec, Canada
$13.5M +$6.55M +70,100 +97%
GLA
49
Great Lakes Advisors
Illinois
$13M -$231K -2,476 -2%
Goldman Sachs
50
Goldman Sachs
New York
$12.8M +$2.97M +31,831 +31%

AMED Hedge Fund Activity: Q4 2023 in Review

287 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q4 2023, worth a combined $3.02B — up 8.1% from $2.79B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new AMED positions and 39 closed out — a net gain of 4 holders — while 111 added to existing stakes and 82 trimmed.

The largest buyer was Fidelity International, opening a new position worth an estimated $122M. The largest seller was Wellington Management Group, exiting entirely with an estimated $91.6M sold.

  • 287 institutional investors held Amedisys (AMED) as of Q4 2023, up from 286 in Q3 2023.
  • Funds reported $3.02B of Amedisys stock for Q4 2023, up 8.1% quarter-over-quarter.
  • 43 funds opened new Amedisys positions in Q4 2023 and 39 closed out, a net change of +4 holders.
  • The largest Amedisys buyer in Q4 2023 was Fidelity International, an estimated $122M added.
  • The largest Amedisys seller in Q4 2023 was Wellington Management Group, an estimated $91.6M sold.

Based on aggregated 13F filings for Q4 2023.